About this trial
This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.
Eligibility criteria
Qualifiers
Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC
Age ≥ 18 years
Receiving definitive chemoradiotherapy
Able and willing to complete electronic questionnaires
Disqualifiers
Severe comorbidities (heart, liver, kidney)
Psychiatric illness or cognitive impairment
Prior chest or mediastinal radiotherapy
Trial design
Treatments tested in this trial
- Electronic Patient-Reported Outcome Monitoring
Treatment groups
Sponsors and collaborators
Qian Chu
Lead sponsor
Tongji Hospital
Sponsor institution